These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11885967)

  • 1. Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists.
    Rashid M; Watanabe M; Nakazawa M; Nakamura T; Hattori K; Nagatom T
    Jpn J Pharmacol; 2001 Nov; 87(3):189-94. PubMed ID: 11885967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane.
    Rashid M; Watanabe M; Nakazawa M; Nagatomo T
    Biol Pharm Bull; 2001 Oct; 24(10):1188-90. PubMed ID: 11642330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane.
    Rashid M; Watanabe M; Nakazawa M; Nagatomo T
    J Pharm Pharmacol; 2002 Aug; 54(8):1123-8. PubMed ID: 12195828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sarpogrelate, a novel 5-HT2 antagonist, on 5-HT-induced endothelium-dependent relaxations in porcine coronary artery.
    Rashid M; Nakazawa M; Nagatomo T
    Jpn J Pharmacol; 2002 Aug; 89(4):405-12. PubMed ID: 12233819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of a newly synthesized 5-HT2 receptor antagonist, AT-1015 (N-[2-[4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino]-ethyl]-1-for myl-4-piperidinecarboxamide monohydrochloride monohydrate), on contraction and relaxation of pig coronary arteries induced by 5-HT and alpha-methylserotonin: comparison with ketanserin.
    Gong H; Rashid M; Nakamura T; Hattori K; Nakazawa M; Kihara H; Yoshimoto R; Nagatomo T
    Biol Pharm Bull; 2000 Sep; 23(9):1105-7. PubMed ID: 10993215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [3H]ketanserin binds to non-5-HT2 sites in rabbit cerebral cortex and neostriatum.
    Dewar KM; Lima L; Reader TA
    Neurochem Res; 1990 May; 15(5):507-14. PubMed ID: 2115148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
    Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
    Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes.
    Nishio H; Inoue A; Nakata Y
    Arch Int Pharmacodyn Ther; 1996; 331(2):189-202. PubMed ID: 8937629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML; Schenck KW; Kurz KD
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
    Titeler M; Lyon RA; Davis KH; Glennon RA
    Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of lipid peroxidation on [3H]ketanserin binding to 5-HT2 prefrontal cortex receptors.
    Rego AC; Oliveira CR
    Neurochem Int; 1995 Dec; 27(6):489-96. PubMed ID: 8574178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.
    Pranzatelli MR
    Biochem Pharmacol; 1991 Aug; 42(5):1099-105. PubMed ID: 1872895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA; Davis KH; Titeler M
    Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2- and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT2-receptors: comparison with ketanserin.
    Korstanje C; Sprenkels R; Doods HN; Hugtenburg JG; Boddeke E; Batink HD; Thoolen MJ; Van Zwieten PA
    J Pharm Pharmacol; 1986 May; 38(5):374-9. PubMed ID: 2872314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of affinities and dissociation potencies of several 5-HT2 antagonists to and from M2 muscarinic receptor in rat heart membranes.
    Rashid M; Muntasir HA; Watanabe M; Nakazawa M; Ozaki M; Nagatomo T
    Biol Pharm Bull; 2003 Aug; 26(8):1184-7. PubMed ID: 12913274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
    Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT2 receptors, roles and regulation.
    Leysen JE; Pauwels PJ
    Ann N Y Acad Sci; 1990; 600():183-91; discussion 192-3. PubMed ID: 2252309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulators.
    Frenken M; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):359-66. PubMed ID: 3110629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two different arterial tissues suggests possible 5-hydroxytryptamine2 receptor heterogeneity.
    Killam AL; Nikam SS; Lambert GM; Martin AR; Nelson DL
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1083-9. PubMed ID: 2319460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors.
    Deliganis AV; Pierce PA; Peroutka SJ
    Biochem Pharmacol; 1991 Jun; 41(11):1739-44. PubMed ID: 1828347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.